Q3 2025 Vitrolife AB Earnings Call Transcript

Oct 23, 2025 / 08:00 AM GMT

Release Date Price: kr134.7

Transcript

Key Points

Positve

Vitrolife AB (VTRLY) achieved 5% organic growth in local currencies, excluding discontinued business, despite macroeconomic and geopolitical challenges.
Sales in the Americas increased by 11% in local currencies, with strong growth across the entire portfolio and all markets in the region.
The company delivered a strong operating cash flow of SEK 255 million, supported by positive contributions from net working capital.
Gross margins remained stable and slightly positive at 58.9%, despite negative currency impacts.
Vitrolife AB (VTRLY) is experiencing early signs of recovery in the IVF cycle growth in the US, with share gains driving growth rates above market averages.

Negative

The reproductive health industry continues to face substantial macroeconomic and geopolitical challenges, impacting overall market conditions.
Sales in APAC increased by only 1%, with China remaining a weak spot due to depressed cycles despite improved reimbursement.
Currency effects negatively impacted sales by 7%, contributing to a 4% decrease in SEK.
The company's EBITDA margin decreased to 30.3% from 33.4% the previous year, mainly due to currency fluctuations and increased investment in IT and digitalization.
Operating expenses increased by SEK 40 million year-over-year, driven by strategic investments in IT and digitalization, impacting overall profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VITR.ST - Vitrolife AB
Q3 2025 Vitrolife AB Earnings Call
Oct 23, 2025 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning, everyone. I would like to welcome you to the Viral Life Group Q3 2025 earnings report. My name is Bronwyn O'Connor, and I'm joined this morning by our new CFO Pad Eriko.

So I will now move you on to the first slide with our Q3 2025 highlights.

I would like to start by highlighting 3 key achievements during the quarter.

The first highlight is that we delivered 5% organic growth in local currencies, excluding discontinued business, despite the fact that the reproductive health industry as a

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.